The GLOW Study: GLP-1 and Lifestyle for Optimal Wellness

NCT07760896 | Not Yet Recruiting

• 1 other identifier: GLOW2026
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn whether a 30-day structured wellness program may support physical and emotional well-being in adults who are already taking a GLP-1 or dual GIP/GLP-1 medication for an FDA-approved indication. The study does not evaluate the GLP-1 medication itself or make changes to participants' medication treatment. The main questions it aims to answer are:

1. 1.Are there changes in participants' physical and emotional well-being after completing the 30-day wellness program?
2. 2.Are there changes in areas such as mood, anxiety, functioning, mindfulness, self-compassion, eating-related behaviors, pain, and positive wellness?
3. 3.Complete online questionnaires before and after the program.
4. 4.Follow the WILD 5 Wellness program for 30 days, which includes daily practices related to exercise, mindfulness, sleep, social connection, and nutrition.
5. 5.Complete a brief online tracking form each day during the 30-day program.

Conditions

Wellness

Keywords

GLP-1; GLP-1 Receptor Agonist; GIP/GLP-1 Receptor Agonist; Lifestyle Intervention; WILD 5 Wellness; Physical Well-Being; Emotional Well-Being; Self-Management

Outcome Measures

Primary Outcomes (1)

• Change in HERO Wellness Scale Total Score From Baseline to Post-Program

  The HERO Wellness Scale is a 5-item self-report measure assessing happiness, enthusiasm, resilience, optimism, and perceived mental wellness. Total scores range from 0 to 50, with higher scores indicating greater mental wellness. The outcome will be the change in total score from pre-program baseline to post-program assessment.

  Baseline and end of 30-day intervention

Secondary Outcomes (10)

• Change in Patient Health Questionnaire-9 (PHQ-9) Total Score From Baseline to Post-Program

  Baseline and end of 30-day intervention

• Change in Generalized Anxiety Disorder-7 (GAD-7) Total Score From Baseline to Post-Program

  Baseline and end of 30-day intervention

• Change in Brief Pain Inventory Average Pain Score From Baseline to Post-Program

  Baseline and end of 30-day intervention

• Change in Cognitive and Physical Functioning Questionnaire (CPFQ) Total Score From Baseline to Post-Program

  Baseline and end of 30-day intervention

• Change in Eating and Appraisal Due to Emotions and Stress (EADES) Total Score From Baseline to Post-Program

  Baseline and end of 30-day intervention

Other Outcomes (2)

• Participant-Reported Change in Selected Substance-Use Behaviors

  End of 30-day intervention

• Post-Program Participant Questionnaire

  End of 30-day intervention

Study Arms (1)

WILD 5 Wellness Program

EXPERIMENTAL

Participants will complete the 30-day WILD 5 Wellness program, which includes daily practices related to exercise, mindfulness, sleep, social connection, and nutrition.

Behavioral: WILD 5 Wellness Program

Interventions

WILD 5 Wellness Program BEHAVIORAL

A 30-day structured wellness program that includes daily practices in five areas: exercise, mindfulness, sleep, social connection, and nutrition. Participants complete the wellness practices independently and complete daily online tracking during the 30-day program.

WILD 5 Wellness Program

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Possess basic skills needed to complete online study forms. Currently prescribed and taking a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist by a licensed healthcare practitioner.
• Report that the medication was prescribed for an FDA-approved indication, such as type 2 diabetes mellitus, chronic weight management for obesity or overweight with at least one weight-related condition, moderate-to-severe obstructive sleep apnea in adults with obesity, or another FDA-approved cardiometabolic indication.
• Willing to complete online consent, registration, program measures, and daily tracking forms.
• Willing to participate in the 30-day WILD 5 Wellness program delivered as part of the GLOW Study.

You may not qualify if:

• Report that the medication was not prescribed for an FDA-approved indication. Pregnant or planning to become pregnant in the next 30 days. Currently have thoughts about harming themselves or someone else. Currently experiencing symptoms suggestive of active psychosis. Unwilling or unable to complete the required online study forms or participate in the 30-day

Sponsors & Collaborators

• Saundra Jain: lead

Study Sites (1)

The GLOW Study

The Colony, Texas, 75056, United States

Location

Related Links

• The GLOW Study website

Study Officials

• Saundra Jain, MA, PsyD, LPC

  The University of Texas at Austin School of Nursing

  PRINCIPAL INVESTIGATOR

• Rakesh Jain, MD, MPH

  Texas Tech University Health Sciences Center School of Medicine - Permian Basin

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Saundra Jain, MA, PsyD, LPC

CONTACT

888-252-7806; saundrajain@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Adjunct Clinical Affiliate

Study Record Dates

• First Submitted: August 7, 2026
• First Posted: August 12, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): October 1, 2027
• Last Updated: August 12, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)